UniQure Aiming To Be First With Hemophilia B Gene Therapy
Presenting 12 Month Data At ASH
The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.
The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.